PathAI and Labcorp have expanded their strategic collaboration, which will enable the deployment of the former’s algorithms in prospective clinical trials of cancer and other diseases.

Developed using Good Clinical Laboratory Practice (GCLP) guidelines and process controls, the PathAI algorithms will be deployed in the broad portfolio of programmes managed by Labcorp Drug Development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest move builds on Labcorp’s previous investment in PathAI and aims to accelerate the use of artificial intelligence (AI)-powered pathology.

PathAI algorithms are locked and validated as fit for purpose and can also be further extended for development and commercialisation of companion diagnostic (CDx) device.

With many potential additional uses, they can also be integrated in retrospective or prospective clinical trials to quantify tissue-based biomarkers and support patient stratification and selection.

PathAI CEO Andy Beck said: “We are very impressed with the vision that Labcorp has for the future of AI-powered pathology in drug development and diagnostics, and we look forward to joining forces to enable our bio-pharma partners to obtain the most accurate, standardized, and data-rich set of pathology readouts from clinical trials to help advance drug development.

“After exploring successful initial projects with Labcorp, we are excited to leverage the scale of its network to grow the reach of digital and computational pathology with the goal of ultimately improving patient outcomes.”

As part of the collaboration, the two companies are also planning to explore bridging the use of AI-powered algorithms from translational research into a clinical laboratory setting.

Labcorp Drug Development CEO Paul Kirchgraber said: “This collaboration will provide our bio-pharma partners a differentiated understanding of relevant patient characteristics through applying leading AI-driven algorithms to support clinical trials from novel biomarker development through patient stratification and companion diagnostic development.”